Skip to content

Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

Eunice Lee Kwak, Yung‐Jue Bang, D. Ross Camidge, Alice Tsang Shaw, Benjamin Solomon, Robert G. Maki, Sai‐Hong Ignatius Ou, Bruce Jeffrey Dezube, Pasi Antero Janne, Daniel Botelho Costa, Marileila Varella‐Garcia, Woo Ho Kim, Thomas James Lynch, Panos M. Fidias, Hannah Stubbs, Jeffrey A. Engelman, Lecia Van Dam Sequist, Weiwei Tan, Leena Gandhi, Mari A. Mino-Kenudson, Greg C. G. Wei, S. Martin Shreeve, Mark J. Ratain, Jeffrey E. Settleman, James G. Christensen, Daniel A. Haber, Keith D. Wilner, Ravi Salgia, Geoffrey Ira Shapiro, Jeffrey William Clark, Anthony John Iafrate

New England Journal of Medicine · 2010 · 4,480 citationsOpen access

No retraction on record in OpenAlex.Check Crossref now

Cite this paper

Kwak, E. L., Bang, Y., Camidge, D. R., Shaw, A. T., Solomon, B., Maki, R. G., Ou, S. I., Dezube, B. J., Janne, P. A., Costa, D. B., Varella‐Garcia, M., Kim, W. H., Lynch, T. J., Fidias, P. M., Stubbs, H., Engelman, J. A., Sequist, L. V. D., Tan, W., Gandhi, L., … Iafrate, A. J. (2010). Anaplastic lymphoma kinase inhibition in Non–Small-Cell lung cancer. New England Journal of Medicine, 363(18), 1693–1703. https://doi.org/10.1056/nejmoa1006448

In text: (Kwak et al., 2010)

Ask a question about this research

One question, free, no account. Anchorcite finds the papers, checks each against Crossref and links every sentence of the answer to the passage it comes from.

Abstract

BACKGROUND: Oncogenic fusion genes consisting of EML4 and anaplastic lymphoma kinase (ALK) are present in a subgroup of non-small-cell lung cancers, representing 2 to 7% of such tumors. We explored the therapeutic efficacy of inhibiting ALK in such tumors in an early-phase clinical trial of crizotinib (PF-02341066), an orally available small-molecule inhibitor of the ALK tyrosine kinase. METHODS: After screening tumor samples from approximately 1500 patients with non-small-cell lung cancer for the presence of ALK rearrangements, we identified 82 patients with advanced ALK-positive disease who were eligible for the clinical trial. Most of the patients had received previous treatment. These patients were enrolled in an expanded cohort study instituted after phase 1 dose escalation had established a recommended crizotinib dose of 250 mg twice daily in 28-day cycles. Patients were assessed for adverse events and response to therapy. RESULTS: Patients with ALK rearrangements tended to be younger than those without the rearrangements, and most of the patients had little or no exposure to tobacco and had adenocarcinomas. At a mean treatment duration of 6.4 months, the overall response rate was 57% (47 of 82 patients, with 46 confirmed partial responses and 1 confirmed complete response); 27 patients (33%) had stable disease. A total of 63 of 82 patients (77%) were continuing to receive crizotinib at the time of data cutoff, and the estimated probability of 6-month progression-free survival was 72%, with no median for the study reached. The drug resulted in grade 1 or 2 (mild) gastrointestinal side effects. CONCLUSIONS: The inhibition of ALK in lung tumors with the ALK rearrangement resulted in tumor shrinkage or stable disease in most patients. (Funded by Pfizer and others; ClinicalTrials.gov number, NCT00585195.).

  1. Cancer statistics, 20222022
  2. Cancer Statistics, 20212021
  3. Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening2011
  4. Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer2016
  5. Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer2015

Metadata from OpenAlex (CC0). Citations are generated from the published record.